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Hormonal therapyBreast cancer is a heterogeneous disease, and within the HER-2 positive subtype this is highly exempli-
fied by the presence of substantial phenotypical and clinical heterogeneity, mostly related to hormonal
receptor (HR) expression. It is well known how HER-2 positivity is commonly associated with a more
aggressive tumor phenotype and decreased overall survival and, moreover, with a reduced benefit from
endocrine treatment. Preclinical studies corroborate the role played by functional crosstalks between
HER-2 and estrogen receptor (ER) signaling in endocrine resistance and, more recently, the activation
of ER signaling is emerging as a possible mechanism of resistance to HER-2 blocking agents. Indeed,
HER-2 positive breast cancer heterogeneity has been suggested to underlie the variability of response
not only to endocrine treatments, but also to HER-2 blocking agents. Among HER-2 positive tumors,
HR status probably defines two distinct subtypes, with dissimilar clinical behavior and different
sensitivity to anticancer agents. The triple positive subtype, namely, ER/PgR/Her-2 positive tumors, could
be considered the subset which most closely resembles the HER-2 negative/HR positive tumors, with sub-
stantial differences in biology and clinical outcome. We argue on whether in this subgroup the ‘‘standard’’
treatment may be considered, in selected cases, i.e., small tumors, low tumor burden, high expression of
both hormonal receptors, an overtreatment. This article review the existing literature on biologic and
clinical data concerning the HER-2/ER/PgR positive tumors, in an attempt to better define the HER-2 sub-
types and to optimize the use of HER-2 targeted agents, chemotherapy and endocrine treatments in the
various subsets.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).i Lauro),
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Breast cancer is a heterogeneous disease, with substantial geno-
typic and phenotypic diversity [1]. HER-2 protein overexpression
or gene amplification is reported in 15–20% of primary breast
carcinomas and is associated with decreased disease free survival
(DFS) and overall survival (OS) [2]. Approximately 70% of invasive
breast cancers express estrogen receptor (ER), and the majority of
ER positive cancers also express progesterone receptor (PgR).
Although the presence of normal PgR levels suggests an intact ER
signal transduction pathway in breast cancer cells, discrepant ER
and PgR expression patterns (ER positive/PgR negative and ER neg-
ative/PgR positive) are sometimes observed. Overall, the ER posi-
tive breast cancers are classified as luminal cancers. These
cancers are further subclassified based on their HER-2 status and
proliferation rate into the ER positive/PgR positive/HER-2 positive
(‘‘triple positive’’) and ER positive/PgR positive/HER-2 negative
subtypes [3–5].
Initially, an inverse association was described between HER-2
positivity and the presence of hormonal receptors (HR), but
subsequently it was reported that 50% of the patients with
HER-2 positive tumors are also HR positive [6], even if HER-2 posi-
tive tumors often, though not always, express HR at lower levels
compared with HR positive/HER-2 negative tumors [7], and
approximately one tenth of HR positive tumors are also HER-2
positive [8].
With regard to treatment, it is commonly believed that HER-2
blocking agents are effective in patients with HER-2-positive dis-
ease, irrespective of HR status [9]. A retrospective evaluation on
the pivotal and other trastuzumab trials showed efficacy indepen-
dently on HR status, thus confirming the paradigm of chemother-
apy and trastuzumab in all the subsets of HER-2 positive disease.
Nevertheless, there are some limitations in the analysis, such as
the semplicistic definition of HR status (positive vs negative),
which does not take into account the degree of HR expression,
and the lack of centralized evaluation [10,11]. Recent data seem
to confirm the hypothesis that some heterogeneity exists among
HER-2 positive subsets, mostly related to HR expression [12].
It is well known how women with HER-2/HR co-positive dis-
ease derive less benefit from endocrine therapy than women with
HER-2 negative/HR positive disease [8,13,14]. Preclinical evidences
seem to confirm that cross-talks between HER-2 and ER signaling
pathways may contribute to resistance to endocrine therapy
[15,16]. Trastuzumab concurrent with tamoxifen or fulvestrant
may inhibit tumor growth and restore tumor sensitivity to these
hormonal agents [17,18]. Therefore, simultaneously inhibition of
both HER-2 and ER pathways is believed more effective than ER
inhibition alone.
Even if treatment with HER-2 targeted agents in early-stage as
well as in advanced HER2 positive BC have shown benefit across
HR status, it is increasingly clear that in HER-2 positive disease
the magnitude of benefit of HER-2 targeted therapy may differ by
HR status. This leads to the question about whether HR status
defines two or more distinct subtypes in HER-2 positive disease
[19]. Moreover, among ER/HER-2 copositive group there is a subset
of ‘‘triple positive’’ (ER/PgR/HER-2 positive) tumors, or tumors with
particularly high degree of HR expression, which might represent a
further and distinct subset with a particularly favorable prognosis,
and for which the combination of standard chemotherapy, Her-2
blockade and endocrine treatment might be considered an
overtreatment.
In this article, we summarize and critically discuss the available
literature data on differences in tumor biology and clinical out-
comes by ER and PgR status in HER-2 positive early and advanced
breast cancer.Epidermal growth factor receptor family and ER pathways
Epidermal Growth Factor Receptor (EGFR) family overexpres-
sion/amplification, resulting in increased phosphorylation of ER,
even in absence of its natural ligand, has been associated with
tamoxifen resistance in vitro [20,21], with EGFR/HER-2 blockade
being shown to both prevent the development of resistance [22],
as well as restoring sensitivity to endocrine treatment in HER-2
overexpressing xenograft models [16,23]. Before the advent of
HER-2 blocking agents, HER-2 positive/HR positive tumors had
unfavorable prognosis compared with HR positive/HER-2 negative
tumors, even if treated with endocrine therapy. In a French regio-
nal retrospective cohort study including 714 small, node-negative
breast cancers treated in ‘‘pre-trastuzumab era’’, the 10 years prog-
nosis of HER-2 positive tumors was worse than that of HER-2 neg-
ative tumors, and the cohort with co-expression of HER-2 and HR
showed the worst prognosis at 10 years. This seems to confirm
the decreased benefit from hormone therapy in the HER-2 posi-
tive/ER positive subset, due to possible cross-talks between the
two pathways, resulting in both intrinsic and acquired resistance
to endocrine agents [13]. Recently, Nahta and O’Regan suggested
that a subset of HER-2 positive/HR positive breast cancers could
be driven primarily by high level of ER expression, and may show
a behavior more similar to HER-2 negative/HR positive breast can-
cers [24]. In recent years, several clinical trials have focused on the
association of both EGFR/HER-2 and HR pathways blockade in
breast cancer patients.
Gefitinib
A phase II randomized, placebo controlled study of 290 patients
with ER positive advanced breast cancer regardless of HER-2 status
compared tamoxifen in combination with either gefitinib or pla-
cebo. In patients with newly diagnosedmetastatic disease or recur-
rence after adjuvant tamoxifen there was a numerical advantage in
progression free survival (PFS) with the combination, which
exceeded the predefined efficacy primary endpoint. Moreover,
even in the small HER-2 positive subset a numerical advantage in
PFS in the gefitinib arm was observed. However, patients recurring
during/after adjuvant aromatase inhibitors (AI) or after having
failed first-line AI did not benefit from combination therapy [25].
The combination of anastrozole and gefitinib vs anastrozole and
placebo has been tested in 93 endocrine-naive patients, with sig-
nificant improvement in PFS favoring the combination arm [26].
The effects of gefitinib have also been explored in a randomized
perioperative study involving 56 patients with ER-positive and
EGFR positive breast cancers, comparing 4–6 weeks of treatment
with a combination of anastrozole and gefitinib vs gefitinib and
placebo. A statistically significant decrease of Ki67 favoring the
combination arm (92.4% vs 98% reduction, p = 0.005) was observed
[27].
Lapatinib
The efficacy of lapatinib in combination with hormonal therapy
as first line treatment for advanced breast cancer in HR positive
and any HER-2 status has been explored in EGF3008, a randomized
placebo controlled study of letrozole and lapatinib vs letrozole and
placebo [28]. One thousand two hundred eighty-six patients were
randomized, with stratification according to time since adjuvant
tamoxifen therapy (<6 vs >6 months). PFS was significantly greater
in the combination arm for the HR positive/HER-2 positive popula-
tion. No additional benefit was seen overall with the addition of
lapatinib in the HER-2 negative cohort. A subsequent blinded
retrospective biomarker evaluation employing immunohistochem-
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tive subgroup there was a significant improvement in PFS with
lapatinib and letrozole combination in patients with low ER
expression, while no benefit was observed with stronger ER
expression [29]. The benefit may be related to inhibition of func-
tional cross-talks between the two pathways, or to an increased
HER-2 sensitivity related to ER inhibition [30]. This data contribute
to support the dynamic interaction between HR and HER-2
signaling.
Trastuzumab
The TAnDEM study was a randomized study of 207 patients
which compared anastrozole plus trastuzumab vs anastrozole in
HR and HER-2 positive MBC. Prior tamoxifen but not chemother-
apy in the adjuvant or metastatic setting was permitted. Both
PFS and response rate were significantly improved in the combina-
tion arm [31]. The eLEc-TRA study randomized 57 HR and HER2
positive patients receiving as first line treatment for advanced dis-
ease letrozole plus trastuzumab or letrozole alone. There was a
numerical but non-statistically significant improvement in PFS
favoring the combination arm. Interestingly, the PFS for those
receiving letrozole with trastuzumab was similar to a cohort of
women who were HR positive/HER2 negative tumours which
received letrozole alone, 14.1 vs 15 months respectively [32].
Recent guidelines on systemic therapy for HER-2 positive/HR
positive advanced breast cancer patients consider endocrine treat-
ment with either trastuzumab or lapatinib or endocrine therapy
alone as an acceptable first-line treatment. Endocrine therapy
alone is included as an option because the trials of endocrine ther-
apy with or without HER2-targeted therapy did not demonstrate a
survival advantage [28,31,33].
Differential efficacy of HER-2 blocking agents and
chemotherapy according to HR status
Even if in patients with HER-2 overexpressing breast cancer
trastuzumab dramatically changed the disease natural history
and improved outcome in all the settings, the pCR rates of neoad-
juvant trastuzumab-containing regimes are still in the range of 30–
60%, with 3-year relapse free survival (RFS) of 71–78% [34], clearly
showing that a substantial number of HER-2 positive breast cancer
patients undergoing surgery still present residual disease despite
prior trastuzumab-based neoadjuvant therapy. Growing evidence
indicates that the response to anti-HER-2 agents and the prognos-
tic impact of pCR after anti-HER-2 based therapy depend on HR
status. Moreover, despite major improvements in outcome,
approximately 15% of patients treated with adjuvant trast-
uzumab-based therapy develop disease recurrence, and all the
patients treated with HER-2 blocking agents for advanced disease
progress, due to intrinsic or acquired resistance [35,36].
Gene expression profiling studies suggested that HER-2 posi-
tive/HR positive and HER-2 positive/HR negative tumors are two
different subtypes, with different prognosis in absence of HER-2
blockade [1,37], confirming their distinct features and behavior.
Moreover, emerging data suggest the involvement of the bidirec-
tional cross-talk between the HER-2 and HR pathways not only
in endocrine resistance but also in resistance to HER-2 blocking
agents [23]. Cross-talks between HER-2 and HR pathways may
intervene in trastuzumab and lapatinib resistance [38]. An increase
in HR signaling was observed in patients with HER-2-positive/HR-
positive tumor treated with lapatinib monotherapy [39–41]. These
data suggest that positive HR status might be also a marker of
lower sensitivity to anti-HER-2 therapies. Recently, ER pathways
have been postulated as means of escape to HER-2 directed ther-
apy. Wang et al. showed that, following lapatinib and trastuzumabtreatment, ER and its downstream effectors increased in all but one
ER positive/HER-2 positive cell lines, and the acquisition of HER-2
directed agents resistance is mediated by activation of ER pathway,
via Bcl2 family members [42]. Another recent study investigated
the cross-talks between HER-2 and ER pathways and the effect of
HER-2 blocking agents on the tyrosine kinase effector transcription
factor Myc, showing that elevated Myc protein was inversely asso-
ciated with pCR. In HER-2 positive cells trastuzumab can repress
Myc transcriptional activity, inhibiting its target gene survivin,
and this correlates with favorable response. Conversely, the
co-expression of ER leads to upregulation of survivin expression
and increased ER transcriptional activity, with subsequent lower
response [43].
Neoadjuvant setting
In the neoadjuvant setting, data from the retrospective study by
Guarneri et al. showed that the addition of trastuzumab to chemo-
therapy produced different outcomes according to HR status, with
pCR rates 1.5 and 2-fold lower in ER positive than in ER negative
cases [44]. More recently, data from the Neo-Sphere, NeoALTTO,
GeparQuinto, ACOSOG Z1041, CALGB 40601, NOAH and TBCRC006
trials further confirmed these findings, showing that pCR rates
were significantly lower in ER-positive than ER-negative tumors,
regardless the type of HER-2 targeted treatment [45–51]. More-
over, the pooled analysis of the German neoadjuvant studies sug-
gested that pCR may be a suitable surrogate endpoint for HER-2
positive/HR negative but not for HER-2 positive/HR positive breast
cancer patients [52].
Thus, patients with HER-2 positive/HR positive tumors not
achieving a pCR are not necessarily at poor prognosis, as are triple
negative subgroup, since adjuvant hormonal treatment may fur-
ther improve clinical outcome. However, in this subgroup the
prognostic value of pCR is lower than in patients with HER-2 posi-
tive/HR negative tumors, the achievement of pCR is infrequent and,
when reported, it does not translate into the favorable outcome as
in the HER-2 positive/HR negative subset [53]. A recent retrospec-
tive study, investigating the prognostic significance of pCR accord-
ing to HR status in 366 patients, showed that among 204 patients
treated with neoadjuvant trastuzumab, the achievement of pCR
was confirmed to be not significantly prognostic in HR positive
subgroup, suggesting that patients with ‘‘triple positive’’ tumors
had a good prognosis despite the lower rate of pCR [54]. Due to
the low rate of pCR in ‘‘triple positive’’ tumors, and its relatively
small prognostic impact, we might speculate to reconsider the
use of hormonal therapy combined with HER-2 blocking agents,
without adding chemotherapy-related toxicity in this subset of
patients.
The HER-2 dual blockade without concurrent chemotherapy
was tested in two phase II neoadjuvant trials [45,51]. TBCRC006
results are particularly intriguing, since 49% of pCR/downstaging
was reported with trastuzumab–lapatinib without chemotherapy,
54% in patients with HR positive tumors receiving also letrozole,
while this percentage was 40% in HR negative group. According
to pCR definition standard criteria, it was 27% overall, 21% in HR
positive tumors, versus 36% in HR negative tumors. Moreover,
the efficacy of trastuzumab and pertuzumab combination, without
chemotherapy, was evaluated in one arm of the NeoSphere trial,
reporting 17% of pCR, but in the subset of patients with HR positive
tumors, not receiving any endocrine treatment, this percentage
was only 6%. Even if pCR rates observed in these two trials are
lower than those reported in studies with chemotherapy, they
raise the hope that HER-2 dual blockade, with endocrine therapy
whenever appropriated (HR positive tumors) might be a reason-
able and well tolerable choice even in neoadjuvant setting.
Recently, alterations of the PI3K and ER pathway genes have been
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ical response rate in patients with HR positive tumors (while not in
HR negative tumors) receiving neoadjuvant chemotherapy and
trastuzumab, suggesting that cross-talks between the two path-
ways are bidirectional and may influence chemotherapy and trast-
uzumab efficacy [55].
A recent retrospective analysis of histopathologic features of
450 HER-2 positive breast cancer patients treated with neoadju-
vant chemotherapy and trastuzumab confirmed that HR positive
and HR negative tumors show distinct histopathologic features,
that may be relevant to their distinct clinical behavior [56].
Adjuvant setting
Similar data are reported also in the adjuvant setting, where a
retrospective evaluation from the HERA trial indicate a clear
advantage in DFS for the trastuzumab arm, but with wider confi-
dence intervals of hazard ratios among patients with HER-2
positive/HR positive tumors [9].
As a confirm of the differential behavior of the two subtypes, HR
positive/HER-2 positive tumors have usually a different timing and
pattern of relapse, since recurrences occur at a relatively constant
rate over time and continue occurring after more than 10–15 years
of follow up. Conversely, HER-2 positive/HR negative tumors
relapse more commonly within the first 5 years. Moreover, sites
of relapse are different, since bone and soft tissue are more com-
mon in ER positive disease, conversely, visceral sites are more fre-
quently observed in ER negative subset, and sensitivity to some
chemotherapy drugs, i.e. paclitaxel, may be different between the
two subsets [57–59]. A recent evaluation of 1187 early breast can-
cers compared disease characteristics among different groups
according to HR and HER-2 status. Results showed that both HR
and HER-2 status had a profound impact on breast cancer charac-
teristics, and triple positive tumors were associated with lower
grade and higher bone involvement, reflecting a retained impact
of HR. Conversely, HER-2 impact on HR positive disease was
reflected by higher grade, younger age and increased frequency
of developing visceral metastases. Moreover, triple positive breast
cancers occurred more frequently in younger patients compared to
ER positive/PgR negative/HER-2 positive subset [30].
Among 123,780 early breast cancers from the California Cancer
Registry, the surrogate classification using ER/PgR/HER-2 and
tumor grade showed a variability in survival among HER-2 sub-
types within each stage of disease, and while survival was superior
across all the stages for ER/PgR positive/HER-2 negative subtype,
the difference was less than 1–2.2% between ER/PgR positive/
HER-2 negative and ER/PgR positive/HER-2 positive subtypes in
early stages, with no significant difference between the two sub-
types in stage 3 [60].
A retrospective evaluation of records from 897 patients with
HER-2 positive/HR positive breast cancers treated with adjuvant
chemotherapy followed or not by hormonal therapy and trast-
uzumab reported higher DFS and OS in patients who had received
chemotherapy, trastuzumab and endocrine therapy than those
observed in patients treated with chemotherapy and trastuzumab
without subsequent endocrine therapy. At multivariate analysis,
administration of endocrine therapy in addition to chemotherapy
and trastuzumab resulted the only independent prognostic factor
for DFS, with a trend in OS, confirming that endocrine treatment
confers benefit when added to chemotherapy and trastuzumab in
patients with HR positive/HER-2 positive early breast cancer [61].
Advanced setting
Some retrospective analyses showed differential sensitivity to
combined HER-2 blocking agents and chemotherapy according toHR status in the advanced setting. A relationship between quanti-
tative immunohistochemical HR expression and response to first-
line chemotherapy and trastuzumab was reported in a retrospec-
tive evaluation on 111 out of 227 HER-2 positive advanced breast
cancer patients, suggesting that an expression of ER in P30% of
tumor cells was predictive of reduced response to chemotherapy
and trastuzumab; moreover, a maintenance endocrine treatment,
added to trastuzumab after chemotherapy in one third of the
patients, translate into significant PFS benefit, indicating a relevant
role of endocrine therapy combined to anti HER-2 agents in this
subset of patients. Conversely, when considering a HR cut off
P1%, in the absence of maintenance endocrine therapy, no differ-
ence in PFS was observed between patients with HR positive and
HR negative tumors. Moreover, a non significant trend toward a
better PFS was observed in patients with tumor expressing high
levels of ER and/or PgR, even in the absence of the maintenance
endocrine therapy [62].
Since the magnitude of benefit of trastuzumab in advanced
HER-2 positive breast cancer varies widely, the clinicopathological
features associated with prolonged first-line trastuzumab-based
treatment duration have been recently investigated in a retrospec-
tive study including 164 patients. Results have shown that long-
term benefit of trastuzumab-based therapy was associated with
HR positivity and the absence of previous adjuvant trastuzumab.
It is noteworthy that a subgroup of patients with HER-2 positive/
HR positive tumors received maintenance trastuzumab and/or
endocrine therapy, which may have favorably influenced the
outcome [63].
A prospective observational study (registHER) on a cohort of
more than 1000 patients with HER-2 positive advanced breast can-
cer, including 530 patients with HER-2 positive/HR positive
tumors, showed that, with or without chemotherapy, outcomes
were more favorable for the HR positive subset, since dual target-
ing of HR and HER-2 pathways was associated with more pro-
longed PFS and OS compared with HER-2 based therapy alone [64].PgR expression role
The role of PgR expression is not completely clarified in terms of
prognostic and predictive significance in breast cancer. So far, the
available literature data suggest its value in predicting endocrine
response in the advanced setting, and retrospective evaluation
from large endocrine adjuvant trials confirm a more favorable
prognosis of patients with tumors expressing both HR [12,65,66],
even when considering numerous bias related to quality testing.
ER positive/PgR negative tumors, as defined by RNA profiling, rep-
resent a distinct subset of breast cancer with more aggressive fea-
tures and poor outcome despite being clinically ER positive [67].
The prognostic value of PgR expression has been already reported
in several studies but, to our knowledge, no prospective study has
focused on HER-2 positive subgroup. Clinical and biological fea-
tures of 31,415 patients with ER/PgR positive tumors were retro-
spectively compared with 13,404 patients with ER positive/PgR
negative tumors. Results showed that the PgR negative subgroup
expressed higher levels of EGFR and HER-2 and displayed more
aggressive features than the ER/PgR copositive subgroup, suggest-
ing that the loss of PgR expression in ER positive tumors may be a
marker of activated EGFR/HER-2 pathway signaling [12]. A signifi-
cant correlation between absence of PgR expression and poorer
outcome in luminal breast cancer was shown in a retrospective
series of 4837 patients with luminal B tumors by immunohisto-
chemical classification. The subset of patients with ER positive/
PgR negative/HER-2 positive tumors had a reduced breast cancer
related survival when compared with the HR positive/HER-2 nega-
tive subgroup; conversely, no statistically significant differences
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patients with HR positive/HER-2 negative tumors, even if it must
be taken into account that the HER-2 positive subset received more
chemotherapy than Her-2 negative subgroup. On this basis, PgR
loss may be considered an unfavorable event even in the HER-2
positive subset [68].
Several studies evaluated the impact of PgR status on recur-
rence and mortality [69–71]. In particular, one trial reported that
women with PgR-negative tumors had a higher risk of mortality
independent on the different characteristics, compared with
women with both HR positive tumors [69]. A recent population-
based study on 1074 patients with early breast cancer confirmed
that the absence of PgR expression was a powerful independent
prognostic variable even in ER positive breast cancer receiving
endocrine therapy, and cancers PgR negative were significantly
more likely to be HER2 positive than PgR positive tumors
(p < 0.001) [72]. The results of the previous reported trial from
the California Cancer Registry showed that the survival of ER/PgR
positive/HER-2 positive subtype was superior to that of ER posi-
tive/PgR negative/HER-2 positive subtype across all stages, con-
firming the relevant role of PgR on survival even in HER-2
positive tumors [60].HER2 blocking plus chemotherapy always?
To date, the paradigm of chemotherapy plus anti-HER-2 agents
is still the mainstay of treatment of all the HER-2 positive breast
cancer subsets, regardless of HR status, even if the molecular het-
erogeneity of HER-2 positive breast cancer may have some thera-
peutic implications. It is largely known how HR positive status,
and the degree of ER expression, reduce chemosensitivity in breast
cancer [73–75].
It is reasonable that the co-expression of both HRs, along with a
high extent of hormonal expression, even if in HER-2 positive
breast cancer, may identify a subset of tumors with a particularly
favorable prognosis, and perhaps less sensitive to chemotherapy
and, probably, to HER-2 blocking agents. We have recently per-
formed a retrospective evaluation on 441 ‘‘triple positive’’ tumors,
all treated with adjuvant chemotherapy and subsequent hormonal
therapy. The series included 158 patients treated with chemother-
apy and endocrine treatment without HER-2 blocking agent in the
‘‘pre-trastuzumab era’’, and 283 patients treated with adjuvant
trastuzumab. The relapse rate at 3 years was 15% in the chemo-
therapy and sequential hormonal adjuvant therapy without trast-
uzumab, and 6.4% in the trastuzumab treated patients (p 0.005).
Kaplan Meyer curves indicated a 5-year RFS and a 5-year OS of
71% and 92%, respectively, in the ‘‘pre-trastuzumab’’ group, while
these estimates raised to 91% and 96.6% in patients having received
chemotherapy, endocrine therapy and trastuzumab. This clearly
confirmed the advantage conferred by trastuzumab administration
even in real practice outside of clinical trials. Conversely, in a small
subset analysis of patients with tumors with ER staining in 50% or
more of cancer cells, the relapse rate at 3 years was 6.2% in the
cohort having received chemotherapy and sequential endocrine
adjuvant therapy without trastuzumab and 5.4% in the cohort hav-
ing received also trastuzumab (p 0.84); Kaplan Meier curves
showed a 5 years RFS of 89.7% and a 5-year OS of 95.7% in the
cohort without trastuzumab, and a 5-year RFS of 92.3% and a
5-year OS of 94.9% in the cohort having received trastuzumab. Not-
withstanding the limitations related to the small sample size and
the low number of recurrences, this evidence seems to suggest that
in ‘‘triple positive’’ patients with tumors expressing very high
degree of HR the addition of trastuzumab to conventional adjuvant
therapy does not provide benefit [76]. We are currently conducting
a larger observational retrospective analysis on ‘‘triple positive’’tumors to better evaluate the correlation among HR status, adju-
vant treatments, endocrine therapy, trastuzumab administration
and outcome, and to better define the role of trastuzumab in this
specific patient subset.
Indeed, HER-2 positive breast cancer heterogeneity has been
suggested to underlie the variability of response to HER-2 blocking
agents, although much remains unknown regarding the precise
genomic and biological features of HER-2 positive cancers, and
underlying mechanisms of de novo or acquired resistance.
Recently, the Cancer Genome Atlas (TCGA) Network has evi-
denced the existence of two genetically distinct HER-2 positive
subtypes, with different mRNA expression, HER-2 enriched or
luminal [77]. Since at least two different HER-2 positive subtypes
exist, HR positive and HR negative, and HR positive/HER-2 positive
tumors are usually enriched with luminal gene cluster, falling into
the luminal B subtype, it is reasonable hypothesizing also distinct
clinical behavior and different sensitivity to anticancer agents.
On the basis of what above reported, the precise identification
and characterization of a HER-2 positive/HR positive subset may
be essential to avoid overtreatment, mainly in patients with small
tumors who could benefit from adjuvant hormonal treatment com-
bined to anti HER-2 agents, possibly without prolonged chemo-
therapy, or without chemotherapy at all. Whether the term
‘‘overtreatment’’ is more strictly related to trastuzumab or to che-
motherapy is still to be clarified. This raises the question if, in
selected cases or specific subgroups of patients, omission of che-
motherapy may be the most appropriate choice and, whether or
not, endocrine treatment combined with HER-2 blocking agents
or HER-2 blockade alone have to be administered, even in the early
setting [78]. Results from neoadjuvant trials testing the HER-2 dual
blockade without chemotherapy seem to confirm this hypothesis,
suggesting that a subgroup exists for which anti-HER-2 treatment
alone in absence of chemotherapy may be effective [45,46], even if
in the HR positive subset the pCR rate in the chemotherapy-free
arms was lower than in HR negative tumors, possibly because
these regimens did not contain endocrine therapy. Moreover,
the results from the small phase II study of Rimawi et al. clearly
confirmed in fact the benefit of adding endocrine manipulation
[51].
In the advanced setting, the dual blockade with trastuzumab
and pertuzumab without chemotherapy produced considerable
response rate and clinical benefit even in patients with HR positive
tumors [79,80]. The combination of trastuzumab and lapatinib
showed significantly longer PFS and OS compared to lapatinib
alone in trastuzumab-refractory patients, half of them with HR
positive tumors [81,82]. However, in the Cleopatra trial patients
with HER-2 positive and HR positive tumors had reduced benefit
in PFS and OS from dual blockade with pertuzumab and trast-
uzumab compared to patients with HR negative tumors, as a con-
firmation of a possible negative interference between HER-2
blocking agents and endocrine pathway [83,84].
Recent ASCO guidelines still recommend as first line treatment
for advanced breast cancer the combination of HER-2 blocking
agents and chemotherapy as the optimal choice, but also consider
the use of endocrine treatment combined with HER-2 target ther-
apy [33]. To date, no trials have directly compared endocrine ther-
apy plus HER2-targeted therapy with chemotherapy plus HER-2-
targeted therapy. Although there seems to be no OS benefit from
adding HER-2-targeted therapy to endocrine therapy, two out of
three studies did show a PFS benefit for the combination therapy
groups [28,31,32], suggesting this combination as a reasonable
option in advanced disease.
The identification of potential biomarkers predictive of HER-2
blocking agents benefit in absence of chemotherapy could signifi-
cantly improve the management of HER-2 positive breast cancer
patients, and a number of studies are ongoing. Potential biomark-
74 P. Vici et al. / Cancer Treatment Reviews 41 (2015) 69–76ers of response to trastuzumab or lapatinib have been recently
investigated by Montemurro et al. in 19 HER-2 positive advanced
breast cancer patients by expression analysis of more than 100
genes from primary tumor samples; PAM-50 intrinsic subtypes
were also identified, along with quantitative HER-2 (H2T) and
p95 protein expression. Median PFS and OS were 7.3 and
43 months, respectively. Biological evaluations showed that high
expression of 17q12-21 amplicon genes HER-2 and belonging to
the PAM50 HER-2 enriched intrinsic profile were associated with
better outcome, suggesting that a subset of patients could be trea-
ted without chemotherapy [85].
Conclusions
Molecular classification is playing an increasingly essential role
in the personalized care of breast cancer, and the three key molec-
ular determinants, HER-2, ER and PgR, are commonly evaluated in
routine clinical practice. However, the biological significance and
complex interactions of their related pathways should be investi-
gated further to determine intrinsic heterogeneity of breast cancer
and inform treatment decisions in the complexities of the clinical
setting, with the identification of further tumor subtypes amenable
to targeted and innovative treatments representing a research
priority.
Overall, the above reported data suggest the possibility that a
subset of small HER-2 positive, ER/PgR positive (‘‘triple positive’’),
breast cancer might be driven primarily by HR status, and biolog-
ically behave more likely HER-2 negative, HR positive breast can-
cers: should these patients receive endocrine treatment in
combination with HER-2 blocking agents, without chemotherapy?
Is the administration of anti-HER-2 agent always necessary? The
identification and characterization of this subset of HER-2 positive
cancers may be essential to avoid possible overtreatment, and
define the role of both HR and HER-2 pathways in the development
of treatment resistance is one of the hallmarks for further investi-
gation, to optimize the use of HER-2 targeting agents, endocrine
therapy and chemotherapy.
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